ANGO

AngioDynamics, Inc.

14.30 USD

Last updated Oct 7, 18:15 UTC

Yesterday HIGH

$15.63

Yesterday LOW

$14.23

52w HIGH

$16.29

52w LOW

$9.39

EPS

-0.07

PE

-204.21

Next Earnings

Oct 20, 2026

Overview News Government Trades Fundamentals

AngioDynamics, Inc. stock is down -6.08% since 30 days ago. The next earnings date is Oct 20, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 39.13% of the previous 22 October’s closed higher than September.

Avi Kapoor

Wed Jun 3, 2026

Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Moving Higher in Wednesday's Pre-Market Session

U.S. stock futures surged on Wed. as Nasdaq futures rose over 7%, driven by AI. Marvell's stock jumped 11.73%.
Benzinga Newsdesk

Wed May 13, 2026

AngioDynamics Announces 2-Yr Results From PRESERVE Pivotal Trial Demonstrating Durable Oncologic Control And Sustained Safety Profile For NanoKnife System In Focal Ablation Of Intermediate-Risk Prostate Cancer

Pivotal U.S. Data Show Sustained Oncologic Control and Safety Profile at 24 monthsResults Presented at AUA 2026AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in
Benzinga Newsdesk

Thu Apr 23, 2026

AngioDynamics Files Patent Infringement Lawsuit Against Endovascular Engineering On April 23, 2026; Seeks Damages And Equitable Relief In Lawsuit Against Endovascular Engineering

-SEC Filing
Benzinga Newsdesk

Mon Apr 6, 2026

Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $16

Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $18 to $16.
Benzinga Newsdesk

Thu Apr 2, 2026

AngioDynamics shares are trading lower. The company reported Q3 financial results and updated its FY26 guidance.
Benzinga Insights

Thu Apr 2, 2026

Earnings Scheduled For April 2, 2026
Benzinga Newsdesk

Thu Apr 2, 2026

AngioDynamics Raises FY2026 Adj EPS Guidance from $(0.33)-$(0.23) to $(0.30)-$(0.23) vs $(0.29) Est; Raises FY2026 Sales Guidance from $312.000M-$314.000M to $313.500M-$315.500M vs $312.881M Est

AngioDynamics (NASDAQ:ANGO) raises FY2026 Adj EPS guidance from $(0.33)-$(0.23) to $(0.30)-$(0.23) vs $(0.29) analyst estimate. Raises FY2026 sales outlook from $312.000 million-$314.000 million to $313.500
Benzinga Newsdesk

Thu Apr 2, 2026

AngioDynamics Q3 Adj. EPS $(0.07) Beats $(0.11) Estimate, Sales $78.423M Beat $76.767M Estimate

AngioDynamics (NASDAQ:ANGO) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.11) by 36.36 percent. This is a 12.5 percent increase over losses of $(0.08) per share from the
Avi Kapoor

Thu Apr 2, 2026

Nasdaq Gains Over 1% On War De-Escalation Hopes: Investor Fear Eases, But Fear & Greed Index Remains In 'Extreme Fear' Zone

Stocks end higher, Fear & Greed Index eases, Trump suggests quick military withdrawal from Iran, earnings disappoint for RH and Nike.
Avi Kapoor

Thu Apr 2, 2026

Acuity, Lindsay And 3 Stocks To Watch Heading Into Thursday

U.S. stock futures trading lower, Acuity and Visionary Holdings report strong earnings, Lindsay Corp expected to post earnings, Globalstar shares jump after Amazon acquisition talks, AngioDynamics expected to report loss.

CLSK $11.56 USD

SPCX $167.20 USD

DRAM DRAM $60.30 USD

VOYG $28.13 USD

SKHY SKHY $179.00 USD

CAT $811.64 USD

FCEL $17.84 USD